Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
04/24 AMGEN INC. (NASDAQ : AMGN) Files An 8-K Entry into a Material Definitive Agreeme..
04/24 AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and..
04/24 AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
04/24 CELGENE CORPORATION (NASDAQ : CELG) Cambridge Expansion Drive Gathers Momentum
04/21 AMGEN : Announces Webcast Of 2017 First Quarter Financial Results
04/18 AMGEN : Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES
04/06 AMGEN, INC. (NASDAQ : AMGN) Submits sBLA Seeking To Expand XGEVA Label
04/06 AMGEN : Files for Xgeva Label Expansion, To Include Myeloma
04/05 APPLICATION FOR MULTIPLE INDICATIONS : AMGN) To US And Europe Regulators
04/04 AMGEN, INC. (NASDAQ : AMGN) To Move Employees From Headquarters In Restructuring..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/25 Notable earnings after Wednesday?s close
04/25 Money flow surges in biotechs, Novartis aims for more early-stage deals
04/24 Amgen to co-promote migraine med erenumab with Novartis in U.S.
04/24 My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
04/24 BIOTECH FORUM DAILY DIGEST : Biotech Lags; Revisiting Radius Health
Advertisement
Financials ($)
Sales 2017 23 012 M
EBIT 2017 11 763 M
Net income 2017 8 141 M
Finance 2017 1 113 M
Yield 2017 2,78%
P/E ratio 2017 14,85
P/E ratio 2018 14,43
EV / Sales 2017 5,17x
EV / Sales 2018 4,55x
Capitalization 120 053 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 186 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
VERTEX PHARMACEUTICALS..59.71%29 231
More Results